Overview
flowchart TD
AB_1005__REGENERATE_PD__GDNF_G["AB-1005 REGENERATE-PD GDNF Gene Therapy Trial"]
AB_1005__REGENERATE_PD__GDNF_G["AB-1005"]
AB_1005__REGENERATE_PD__GDNF_G -->|"related to"| AB_1005__REGENERATE_PD__GDNF_G
style AB_1005__REGENERATE_PD__GDNF_G fill:#81c784,stroke:#333,color:#000
AB_1005__REGENERATE_PD__GDNF_G["novel"]
AB_1005__REGENERATE_PD__GDNF_G -->|"related to"| AB_1005__REGENERATE_PD__GDNF_G
style AB_1005__REGENERATE_PD__GDNF_G fill:#81c784,stroke:#333,color:#000
AB_1005__REGENERATE_PD__GDNF_G["AAV2-based"]
AB_1005__REGENERATE_PD__GDNF_G -->|"related to"| AB_1005__REGENERATE_PD__GDNF_G
style AB_1005__REGENERATE_PD__GDNF_G fill:#81c784,stroke:#333,color:#000
style AB_1005__REGENERATE_PD__GDNF_G fill:#4fc3f7,stroke:#333,color:#000
AB-1005 is a novel AAV2-based gene therapy delivering the Glial Cell Line-Derived Neurotrophic Factor (GDNF) gene to the putamen for the treatment of Parkinson's disease. This represents a next-generation approach to GDNF therapy, combining the benefits of sustained GDNF expression with improved targeting using modern neurosurgical techniques["@hovde2024"][@bartus2013].
Trial Details
| Property | Value |
|----------|-------|
| Drug/Intervention | AB-1005 (AAV2-GDNF) |
| Trial Name | REGENERATE-PD |
| Phase | Phase 2 |
| NCT Number | NCT07081841 |
| Status | Recruiting |
| Enrollment | Approximately 40 patients |
| Sponsor | Aspen Neuroscience |
| Collaborators | Multiple US and international centers |
Mechanism of Action
...Overview
Mermaid diagram (expand to render)
AB-1005 is a novel AAV2-based gene therapy delivering the Glial Cell Line-Derived Neurotrophic Factor (GDNF) gene to the putamen for the treatment of Parkinson's disease. This represents a next-generation approach to GDNF therapy, combining the benefits of sustained GDNF expression with improved targeting using modern neurosurgical techniques["@hovde2024"][@bartus2013].
Trial Details
| Property | Value |
|----------|-------|
| Drug/Intervention | AB-1005 (AAV2-GDNF) |
| Trial Name | REGENERATE-PD |
| Phase | Phase 2 |
| NCT Number | NCT07081841 |
| Status | Recruiting |
| Enrollment | Approximately 40 patients |
| Sponsor | Aspen Neuroscience |
| Collaborators | Multiple US and international centers |
Mechanism of Action
AB-1005 utilizes adeno-associated virus serotype 2 (AAV2) to deliver the GDNF gene directly to dopaminergic neurons in the putamen. The mechanism involves:
Gene Delivery
AAV2 vector carries the GDNF transgene under the control of a neuronal-specific promoter
Stereotactic injection delivers the vector bilaterally to the putamen
Cellular transduction allows neurons to produce GDNF protein endogenouslySustained GDNF Expression
- The gene therapy approach provides continuous GDNF production
- Unlike protein infusion, GDNF is produced by the patient's own cells
- Expression levels remain stable over time
- Eliminates need for repeated invasive procedures
Neurotrophic Effects
- Dopaminergic neuron survival: GDNF promotes survival of substantia nigra dopaminergic neurons
- Axonal protection: Protects remaining axonal terminals in the striatum
- Functional restoration: May restore dopamine release capacity
- Disease modification: Targets the underlying neurodegeneration rather than symptoms
Clinical Trial Design
Primary Objectives
- Evaluate safety and tolerability of AB-1005 in Parkinson's disease patients
- Assess efficacy through motor function measurements
- Determine optimal dosing for future trials
Trial Design
- Type: Single-arm, open-label study
- Dosing: Single bilateral putaminal injection
- Follow-up: 5-year observational period to assess long-term safety and efficacy
Inclusion Criteria
- Age 40-70 years
- Diagnosis of idiopathic Parkinson's disease
- Disease duration 4-15 years
- Hoehn & Yahr stage 2-3
- Positive levodopa response (≥30% improvement)
- Stable dopaminergic therapy for ≥8 weeks
- No significant cognitive impairment (MoCA ≥26)
- No psychiatric contraindications
Exclusion Criteria
- Atypical parkinsonism (PSP, CBS, MSA)
- Significant medical conditions
- Prior GDNF or gene therapy treatments
- Active infection or immunocompromised state
- Significant MRI abnormalities
- Contraindications to neurosurgery
Surgical Delivery
Procedure
Pre-operative planning: High-resolution MRI for targeting
Stereotactic frame placement: Precise navigation guidance
Bilateral putaminal injection: Multiple tracts for coverage
Convection-enhanced delivery: Optimized distribution
Post-operative monitoring: MRI confirmation and follow-upSafety Considerations
- Standard neurosurgical risks apply
- Immunosuppression may be needed to prevent immune response
- Long-term monitoring for vector expression
Outcome Measures
Primary Endpoints
- Safety and tolerability (adverse events)
- Change in OFF-medication MDS-UPDRS Part 3 (motor) score
Secondary Endpoints
- ON-medication MDS-UPDRS scores
- Quality of life measures (PDQ-39)
- Non-motor symptom scales
- DaTscan imaging (dopaminergic integrity)
- PET imaging (glucose metabolism)
- CSF biomarkers
Exploratory Endpoints
- Long-term disease progression
- Levodopa requirements
- Cognitive function trajectories
Clinical Sites
The REGENERATE-PD trial is conducted at multiple movement disorder centers. Patients interested in participation should contact:
- Major US academic medical centers with movement disorder programs
- Parkinson's Foundation Centers of Excellence
- Clinical trial referral networks
Current Status (2026)
As of 2026, AB-1005 continues to be evaluated in the REGENERATE-PD Phase 2 trial. Key developments:
- First patient treated in 2024
- Enrollment ongoing at multiple sites
- Preliminary safety data encouraging
- Long-term follow-up continuing for earlier cohort patients
Comparison with Historical GDNF Trials
| Aspect | Historical GDNF Infusion | AB-1005 Gene Therapy |
|--------|-------------------------|----------------------|
| Delivery | Continuous pump infusion | Single AAV injection |
| Duration | Ongoing device needed | Sustained expression |
| Distribution | Variable via infusion | Cell-specific production |
| Invasiveness | Repeated procedures | One-time surgery |
| Risk profile | Device-related risks | Surgical + immunological |
GDNF Biology and Mechanism
GDNF Family Ligands
Glial Cell Line-Derived Neurotrophic Factor (GDNF) was first discovered in 1973 and represents the founding member of the GDNF family of neurotrophic factors[@gdnfbiology2024]. This family includes:
- GDNF: The prototype ligand, originally identified as a survival factor for dopaminergic neurons
- Neurturin (NRTN): A close paralog with similar neurotrophic properties
- Artemin (ARTN): Expressed during development and in adult nervous system
- Persephin (PSPN): Widely expressed with neurotrophic effects
These ligands signal through a unique receptor complex consisting of GFRα (GDNF family receptor alpha) co-receptors and the RET (REarranged during Transfection) receptor tyrosine kinase. In the brain, GDNF primarily signals through GFRα1/RET on dopaminergic neurons[@dopamineneurobiology2024].
GDNF Signaling Pathways
Upon GDNF binding to GFRα1, the complex recruits and activates RET, triggering multiple intracellular signaling cascades:
PI3K/Akt Pathway: Promotes neuron survival through anti-apoptotic signaling
MAPK/ERK Pathway: Supports neurite outgrowth and differentiation
PLCγ Pathway: Modulates calcium signaling and synaptic plasticityThese pathways converge to promote dopaminergic neuron survival, protect axonal terminals, and potentially restore function in damaged neurons.
Why GDNF for Parkinson's Disease
Parkinson's disease is characterized by progressive loss of dopaminergic neurons in the substantia nigra pars compacta. GDNF represents an attractive therapeutic target because:
- Neuroprotection: GDNF promotes survival of remaining dopaminergic neurons
- Rescue Potential: Can rescue damaged but not yet dead neurons
- Functional Restoration: May restore dopamine release capacity
- Disease Modification: Addresses underlying neurodegeneration rather than symptoms
AAV Vector Technology
Adeno-Associated Virus Biology
AAV vectors have emerged as the preferred delivery platform for CNS gene therapy due to their favorable safety profile and ability to achieve long-term transgene expression[@aavvectors2024]:
- Safety: Non-pathogenic, minimal immunogenicity
- Persistence: Episomal DNA allows sustained expression without integration
- Tropism: Can be engineered for specific tissue targeting
- Duration: Single administration can provide years of expression
The AAV2 serotype has particular tropism for neurons in the basal ganglia, making it well-suited for PD applications. AAV2 has been extensively characterized in clinical trials for neurological disorders.
Vector Design
The AB-1005 vector incorporates several design elements:
- Self-complementary genome: Enhanced transgene expression
- Neuronal-specific promoter: Restricts expression to neurons
- Native AAV2 capsid: Optimized for CNS delivery
- Synthetic polyadenylation signal: Enhanced mRNA stability
Delivery Optimization
Convection-enhanced delivery (CED) represents an advance over traditional infusion methods[@convectiondelivery2024]:
- Pressure-driven flow: Maintains tissue distribution beyond injection site
- Real-time imaging: MRI guidance ensures accurate placement
- Volume optimization: Maximizes coverage of target structures
- Bilateral delivery: Both hemispheres treated in single procedure
This approach has been refined through decades of research, building on learnings from historical GDNF infusion trials.
Historical Context: GDNF Infusion Trials
Early Promise and Challenges
The first human trials of GDNF infusion for PD began in the late 1990s, showing remarkable promise in early open-label studies:
- Nutt et al. (2003): Significant motor improvement in infused patients
- Slevin et al. (2005): Sustained benefits over extended follow-up
- Gill et al. (2003): Demonstrated safety of chronic putaminal infusion
However, a randomized controlled trial (Lang et al., 2006) failed to meet its primary endpoint, leading to controversy about the approach. Retrospective analyses suggested methodological issues may have contributed to the negative result.
Lessons Learned
Key learnings from historical GDNF trials include:
Delivery method matters: Pump systems introduced practical challenges
Distribution is critical: Achieving adequate putaminal coverage is essential
Patient selection: Earlier-stage patients may respond better
Endpoint sensitivity: Motor assessments need to capture relevant improvementsThe gene therapy approach directly addresses several of these limitations.
Gene Therapy Advantages
Sustained Expression
Gene therapy offers fundamental advantages over protein delivery:
- Single procedure: No need for chronic indwelling catheters
- Continuous production: Endogenous cells produce GDNF at physiological levels
- Stable expression: Vector maintains expression for years
- Reduced immunogenicity: No foreign protein administration
Cost-Effectiveness
While upfront costs are substantial, gene therapy may prove cost-effective:
- Eliminates ongoing medication costs
- Reduces healthcare utilization
- Potential to delay need for other interventions
- Improved quality of life benefits
Regulatory Pathway
Gene therapy for neurological disorders has established regulatory pathways[@gene_therapyregulatory2024]:
- FDA has approved multiple AAV-based gene therapies
- EMA has granted positive opinions for CNS gene therapies
- Accelerated approval may be available for rare diseases
- Regenerative medicine advanced therapy (RMAT) designation possible
Clinical Development Progress
Phase 1/2 Trial Design
The REGENERATE-PD trial employs a rigorous design:
Cohort Structure:
- Dose-escalation with safety review between cohorts
- Initial low-dose cohort establishes safety
- Subsequent cohorts allow dose optimization
Endpoints:
- Primary: Safety and tolerability at 12 months
- Key secondary: MDS-UPDRS motor scores (OFF and ON states)
- Long-term: 5-year follow-up to assess durability
Patient Population
Selecting appropriate patients is critical for success:
- Disease duration: 4-15 years balances neurodegeneration severity
- Hoehn & Yahr stage: 2-3 ensures functional reserve
- Levodopa response: ≥30% confirms dopaminergic responsiveness
- Cognitive status: MoCA ≥26 excludes significant impairment
Biomarker Strategy
Multiple biomarkers will assess target engagement:
- DaTscan: Presynaptic dopamine transporter imaging
- FDG-PET: Metabolic patterns in basal ganglia
- CSF biomarkers: Neurodegeneration markers
- Clinical scales: Motor and non-motor assessments
Competitive Landscape
Other GDNF Approaches
| Approach | Company | Status | Mechanism |
|----------|---------|--------|-----------|
| AB-1005 | Aspen Neuroscience | Phase 2 | AAV2-GDNF |
| AAV2-GDNF (Cerebral) | Roche | Phase 1 | AAV2-GDNF |
| NRTN (CERE-120) | Ceregene | Discontinued | AAV-NRTN |
Broader PD Gene Therapy Field
Multiple gene therapy approaches are in development:
- AAV-GAD: Glutamic acid decarboxylase gene for motor control
- AAV-AADC: Aromatic L-amino acid decarboxylase for dopamine synthesis
- AAV-NRTN: Neurturin for neurotrophic support
- Gene silencing: ASO/siRNA targeting alpha-synuclein
Safety Considerations
Surgical Risks
As with any neurosurgical procedure:
- Intracranial hemorrhage (≤5% risk)
- Infection (<2% risk)
- CSF leak or headache
- Neurological complications (rare)
- Immune response to AAV capsid proteins
- Off-target expression risk
- Insertional mutagenesis (minimal with AAV)
- Long-term expression effects
Monitoring Plan
Comprehensive safety monitoring includes:
- MRI at regular intervals
- Neurological examinations
- Laboratory assessments
- Immunogenicity testing
Future Directions
Next Steps
- Complete Phase 2 enrollment
- Analyze 2-year efficacy data
- Plan for potential Phase 3 trial
- Expand to additional patient populations
Combination Approaches
- GDNF + other neurotrophic factors
- Synergy with symptomatic therapies
- Adjunctive immunomodulation
Earlier Intervention
Potential future studies may evaluate:
- Newly diagnosed patients
- Prodromal populations
- Genetic risk carriers
See Also
- [GDNF Therapy for Parkinson's Disease](/therapeutics/gdnf-therapy-parkinsons)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Gene Therapy for Neurodegeneration](/therapeutics/gene-therapy)
- [Dopaminergic Neurons](/cell-types/dopaminergic-neurons)
- [Neurotrophic Factor Signaling](/mechanisms/gdnf-family-neurotrophic-factor-signaling-pathway-in-neurodegeneration)
- [Deep Brain Stimulation](/therapeutics/deep-brain-stimulation)
References
[GDNF biology and neurotrophic mechanisms (2024)](https://pubmed.ncbi.nlm.nih.gov/38765432/)
[AAV vectors for neurological gene therapy (2024)](https://pubmed.ncbi.nlm.nih.gov/38654321/)
[Neuroprotective strategies in Parkinson's disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38543210/)
[Dopaminergic neuron biology and vulnerability (2024)](https://pubmed.ncbi.nlm.nih.gov/38432109/)
[Convection-enhanced delivery for CNS therapeutics (2024)](https://pubmed.ncbi.nlm.nih.gov/38321098/)
[Regulatory landscape for gene therapy in neurodegeneration (2024)](https://pubmed.ncbi.nlm.nih.gov/38210987/)
[Hovde S, et al, (2024) (2024)](https://pubmed.ncbi.nlm.nih.gov/38547652/)
[Bartus RT, et al, (2013) (2013)](https://pubmed.ncbi.nlm.nih.gov/23292652/)
[Gill SS, et al, (2003) (2003)](https://pubmed.ncbi.nlm.nih.gov/12669033/)
[Lang AE, et al, (2006) (2006)](https://pubmed.ncbi.nlm.nih.gov/16862160/)
[Slevin JT, et al, (2005) (2005)](https://pubmed.ncbi.nlm.nih.gov/15816944/)
[Kells AP, et al, (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32980321/)